Sandoz Is Satisfied With US Pegfilgrastim Start
Promising Initial Signs For Ziextenzo
Executive Summary
Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.
You may also be interested in...
Sandoz Study Highlights Saving Potential Of Pegfilgrastim Biosimilar
Sandoz has published the results of two studies involving the company’s pegfilgrastim biosimilar and glatiramer acetate generic. For the former, Sandoz observed cost savings could run eventually to tens of millions of dollars per year with patient conversion and expanded access.
Sandoz Looks To Biosimilars As It Reprioritizes In The US
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.
Sandoz Optimistic On Biosimilars As It Reprioritizes US Portfolio
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: